3D-CRT	Three-Dimensional Conformal Radiotherapy
ADC	Apparent Diffusion Coefficient
ADCs	Antibody-Drug Conjugates
AI	Artificial Intelligence
AMF	Alternating Magnetic Field
ASCO	American Society of Clinical Oncology
ASTRO	American Society for Radiation Oncology
BBB	Blood–Brain Barrier
BEV	Bevacizumab
BNCT	Boron Neutron Capture Therapy
BSH	Sodium Borocaptate
CDK4/6	Cyclin-Dependent Kinases 4 and 6
CDKN2A/B	Cyclin-Dependent Kinase Inhibitor 2A/B
CFRT	Conventional Fractionated Radiotherapy
Cho	Choline
CIRT	Carbon Ion Radiotherapy
Cr	Creatine
CRT	Chemoradiation
CT	Chemotherapy
CTV	Clinical Target Volume
ddTMZ	Dense Dose Temozolomide
DSC	Dynamic Susceptibility Contrast Perfusion
DWI	Diffusion-Weighted Imaging
EGFR	Epidermal Growth Factor Receptor
EORTC	European Organisation for Research and Treatment of Cancer
ESCAT	ESMO Scale for Clinical Actionability of Molecular Targets
ESTRO	European Society for Radiotherapy and Oncology
EANO	European Association of Neuro-Oncology
FSRT	Fractionated Stereotactic Radiotherapy
GBM	Glioblastoma Multiforme
GTV	Gross Tumor Volume
GyE	Gray Equivalent
HFRT	Hypofractionated Radiotherapy
HIF-1α	Hypoxia-Inducible Factor 1-Alpha
HR	Hazard Ratio
HSRT	Hypofractionated Stereotactic Radiotherapy
ICI	Immune Checkpoint Inhibitor
IDH	Isocitrate Dehydrogenase
IGRT	Image-Guided Radiotherapy
IMPT	Intensity-Modulated Proton Therapy
IMRT	Intensity-Modulated Radiotherapy
MDSCs	Myeloid-Derived Suppressor Cells
KPS	Karnofsky Performance Status
L-BPA	L-4-Boronophenylalanine
LITT	Laser Interstitial Thermal Therapy
MDACC	MD Anderson Cancer Center
mEHT	Modulated Electrohyperthermia
MHT	Magnetic Hyperthermia
MNP	Magnetic Nanoparticles
mOS	Median Overall Survival
MRI	Magnetic Resonance Imaging
MRS	Magnetic Resonance Spectroscopy
MRgRT	Magnetic Resonance-Guided Radiotherapy
NAA	N-Acetyl Aspartate
NAT	Neoadjuvant Therapy
NCCN	National Comprehensive Cancer Network
NICE	National Institute for Health and Care Excellence
nGBM	Newly Diagnosed Glioblastoma Multiforme
OS	Overall Survival
PARP	Poly (ADP-Ribose) Polymerase
PET	Positron Emission Tomography
PFS	Progression-Free Survival
PI3K/AKT	Phosphatidylinositol 3-Kinase/Protein Kinase B
PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
PT	Proton Therapy
PTEN	Phosphatase and Tensin Homolog
PTV	Planning Target Volume
RANO	Response Assessment in Neuro-Oncology
RBE	Relative Biological Effectiveness
rGBM	Recurrent Glioblastoma Multiforme
RT	Radiotherapy
RCTs	Randomized Controlled Trials
SRS	Stereotactic Radiosurgery
SVZ	Subventricular Zone
TAT	Targeted Alpha Therapy
TCGA	The Cancer Genome Atlas
TCP	Tumor Control Probability
TERT	Telomerase Reverse Transcriptase
TMZ	Temozolomide
TP53	Tumor Protein p53
TTFields	Tumor Treating Fields
V20Gy	Volume Receiving 20 Gray
V40Gy	Volume Receiving 40 Gray
VMAT	Volumetric Modulated Arc Therapy
WBRT	Whole-Brain Radiotherapy
WHO	World Health Organization
wt	Wild-Type